|Bid||0.00 x 1000|
|Ask||0.00 x 1400|
|Day's Range||28.87 - 29.33|
|52 Week Range||21.70 - 54.00|
|Beta (3Y Monthly)||2.08|
|PE Ratio (TTM)||225.04|
|Earnings Date||Jul 30, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||48.00|
NEW YORK, NY / ACCESSWIRE / June 21, 2019 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (STAA). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. The investigation concerns whether STAAR and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
The Zacks Analyst Blog Highlights: Herman Miller, Clean Harbors, Great Lakes Dredge & Dock and STAAR Surgical
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! STAAR Surgical Company (NASDAQ:STAA) shareholders might be concerned after seeing the share p...
Insider Monkey finished processing more than 700 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of December 31st, 2018. What do these smart investors think about STAAR Surgical Company (NASDAQ:STAA)? STAAR Surgical Company (NASDAQ:STAA) investors should pay attention to a decrease in support from the world's […]
The Monrovia, California-based company said it had net income of 3 cents per share. Earnings, adjusted for non-recurring costs, came to 10 cents per share. The maker of implantable lenses posted revenue ...
STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced the leading refractive ophthalmic societies in Germany and Japan have increased the diopter range for recommended use of phakic refractive lenses, including the EVO Visian ICL, to -3.0 diopters from -6.0 diopters. A diopter is a unit of measure of the refractive power of a lens and correlates with the patient’s level of nearsightedness (myopia/distance vision needs).
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. By way of learning-by-doing, w...
STAAR Surgical Company (STAA), a leading developer, manufacturer, and marketer of implantable lenses and companion delivery systems for the eye, today announced that more than one million Visian implantable Collamer lenses (ICLs) have been implanted globally. “We celebrate the Visian ICL one million lens milestone with our ophthalmology partners, clinicians, and patients who are elevating the ICL to the premium and primary solution for refractive based vision correction,” said Caren Mason, President and CEO of STAAR Surgical Company.
NEW YORK, April 09, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the first quarter ended March 29, 2019 on Wednesday, May 1, 2019 after the market close. STAAR will host a conference call and webcast on Wednesday, May 1 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Conference ID 2299537), please dial 855-765-5684 for domestic participants and 262-912-6252 for international participants.
LOS ANGELES, March 01, 2019 -- Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of STAAR Surgical Company (NASDAQ: STAA) investors concerning the.
STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced a Strategic Cooperation Agreement with Vista Oftalmólogos, a 49-clinic ophthalmology group spanning Spain, France, Portugal and Morocco with more than 200 eye doctors and 1,000 employees. The agreement positions the EVO Visian ICL™ family of lenses as a premium and primary refractive procedure for patients suffering from nearsightedness (myopia), which is the need for distance vision correction. “Providing the highest level of science-backed vision services to ensure satisfied patients is the common endeavor of every Vista clinic and the EVO Visian ICL fulfills that goal fitting seamlessly into our clinics,” said Mr. Juan Borreguero, Manager of Vista Oftalmólogos.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Today we are going to look at STAAR Surgical CompanyRead More...